SPA
CSTL icon

Sherbrooke Park Advisers’s Castle Biosciences CSTL Stock Holding History

Sherbrooke Park Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,439
Closed -$389K – 566
2025
Q1 		$389K Buy
19,439
+7,067
+57% +$175K 0.18% 208
2024
Q4 		$330K Sell
12,372
-1,789
-13% -$54.5K 0.11% 357
2024
Q3 		$404K Buy
+14,161
New +$360K 0.09% 417
2024
Q2 		– Sell
-20,825
Closed -$461K – 965
2024
Q1 		$461K Buy
+20,825
New +$453K 0.09% 390

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Sherbrooke Park Advisers's CSTL Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 19,439 shares — an estimated $389K sold.

Sherbrooke Park Advisers first reported a position in CSTL in Q1 2024 and held it in 4 quarters. The position peaked at $461K in Q1 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 19,439 Castle Biosciences shares in Q2 2025, an estimated $389K.
  • Sherbrooke Park Advisers first reported a position in Castle Biosciences in Q1 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Castle Biosciences position peaked at $461K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.